Strategic Partnerships Fresenius Kabi is actively pursuing and expanding collaborations, such as integrating TQ Therapeutics' cell isolation tech into its Cue Cell Processing System and licensing PB016 vedolizumab with Polpharma Biologics. This indicates strong opportunities to pursue co-development, licensing deals, and joint go-to-market arrangements with biotech firms and hospital systems to broaden cell therapy, biosimilar, and autoimmune oncology portfolios.

Healthcare Leadership As a global leader in blood collection bags and devices and with a broad nutrition and infusion portfolio, there is a clear opportunity to sell comprehensive hospital and blood bank solutions. Develop bundled offerings of infusion pumps, disposables, clinical nutrition products, and blood bank equipment to large health systems, operating rooms, ICUs, and transfusion services through multi-year contracts.

Delivery Innovations Recent launches like room temperature stable rocuronium injections and expanded cell therapy devices present a compelling case to target anesthesia, surgical suites, and ICU procurement teams. Position stable formulations and advanced delivery devices as cost-saving, safety-enhancing choices that simplify storage, handling, and administration.

Digital Ecosystem Fresenius Kabi’s tech stack including Veeva, Cherwell, Shopify, and blockchain readiness offers avenues for digital-enabled sales and supply chain collaboration. Propose enterprise CRM-driven account management, digital procurement, regulatory and recalls management services, and data-integrated product rollouts to improve customer experience and compliance.

Quality & Sustainability The 2025 Famotidine recall underscores QA risk but also creates a doorway to emphasize robust quality assurance, supply continuity, and sustainability commitments. Offer QA and supplier audits, recalls readiness programs, and sustainability-aligned sourcing partnerships to healthcare providers seeking reliable, ethical, and resilient supplier relationships.